AKT1 and pancreatic neoplasm: Metformin's antitumor effects, however, occur without stimulating Akt and ERK activation, and therefore, metformin in combination with mTOR inhibitors represents a future direction to improve clinical efficacy in pancreatic cancer (Soares et al., 2013).